» Articles » PMID: 21085663

Amyloid-β Oligomer Specificity Mediated by the IgM Isotype--implications for a Specific Protective Mechanism Exerted by Endogenous Auto-antibodies

Overview
Journal PLoS One
Date 2010 Nov 19
PMID 21085663
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Alzheimers disease (AD) has been strongly linked to an anomalous self-assembly of the amyloid-β peptide (Aβ). The correlation between clinical symptoms of AD and Aβ depositions is, however, weak. Instead small and soluble Aβ oligomers are suggested to exert the major pathological effects. In strong support of this notion, immunological targeting of Aβ oligomers in AD mice-models shows that memory impairments can be restored without affecting the total burden of Aβ deposits. Consequently a specific immunological targeting of Aβ oligomers is of high therapeutic interest.

Methodology/principal Findings: Previously the generation of conformational-dependent oligomer specific anti-Aβ antibodies has been described. However, to avoid the difficult task of identifying a molecular architecture only present on oligomers, we have focused on a more general approach based on the hypothesis that all oligomers expose multiple identical epitopes and therefore would have an increased binding to a multivalent receptor. Using the polyvalent IgM immunoglobulin we have developed a monoclonal anti-Aβ antibody (OMAB). OMAB only demonstrates a weak interaction with Aβ monomers and dimers having fast on and off-rate kinetics. However, as an effect of avidity, its interaction with Aβ-oligomers results in a strong complex with an exceptionally slow off-rate. Through this mechanism a selectivity towards Aβ oligomers is acquired and OMAB fully inhibits the cytotoxic effect exerted by Aβ(1-42) at highly substoichiometric ratios. Anti-Aβ auto-antibodies of IgM isotype are frequently present in the sera of humans. Through a screen of endogenous anti-Aβ IgM auto-antibodies from a group of healthy individuals we show that all displays a preference for oligomeric Aβ.

Conclusions/significance: Taken together we provide a simple and general mechanism for targeting of oligomers without the requirement of conformational-dependent epitopes. In addition, our results suggest that IgM anti-Aβ auto-antibodies may exert a more specific protective mechanism in vivo than previously anticipated.

Citing Articles

Antibody production and characterization of the nucleoprotein of sever fever with thrombocytopenia syndrome virus (SFTSV) for effective diagnosis of SFTSV.

Lee K, Choi M, Cho M, Choi D, Bhoo S Virol J. 2023; 20(1):206.

PMID: 37679757 PMC: 10486111. DOI: 10.1186/s12985-023-02173-1.


Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.

Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja A Transl Neurodegener. 2021; 10(1):38.

PMID: 34579778 PMC: 8477473. DOI: 10.1186/s40035-021-00258-x.


Amphiphilic Distyrylbenzene Derivatives as Potential Therapeutic and Imaging Agents for Soluble and Insoluble Amyloid β Aggregates in Alzheimer's Disease.

Sun L, Cho H, Sen S, Arango A, Huynh T, Huang Y J Am Chem Soc. 2021; 143(27):10462-10476.

PMID: 34213901 PMC: 8762579. DOI: 10.1021/jacs.1c05470.


Peripheral Routes to Neurodegeneration: Passing Through the Blood-Brain Barrier.

Giannoni P, Claeysen S, Noe F, Marchi N Front Aging Neurosci. 2020; 12:3.

PMID: 32116645 PMC: 7010934. DOI: 10.3389/fnagi.2020.00003.


Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-β in the Amyloid Pathology.

Oh S, Kim J, Park S, Lee J Int J Mol Sci. 2020; 21(3).

PMID: 31991844 PMC: 7037199. DOI: 10.3390/ijms21030802.


References
1.
Hartley D, Zhao C, Speier A, Woodard G, Li S, Li Z . Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem. 2008; 283(24):16790-800. PMC: 2423271. DOI: 10.1074/jbc.M802215200. View

2.
Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N . Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A. 2003; 100(11):6370-5. PMC: 164453. DOI: 10.1073/pnas.1237107100. View

3.
Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M . Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs. 2010; 70(5):513-28. DOI: 10.2165/11533070-000000000-00000. View

4.
Smith D, Chen X, Iwata A, Graham D . Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg. 2003; 98(5):1072-7. DOI: 10.3171/jns.2003.98.5.1072. View

5.
Szabo P, Relkin N, Weksler M . Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008; 7(6):415-20. DOI: 10.1016/j.autrev.2008.03.007. View